brn 2068482

Neratinib maleate monohydrate is an irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity.

Neratinib-D6 (Standard) is a reference standard of Neratinib-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Neratinib-d6 is the deuterated form of Neratinib. Neratinib (HKI-272) is an orally active, irreversible tyrosine kinase inhibitor that suppresses the activity of HER2 and EGFR, with IC50 values of 59 nM and 92 nM, respectively.

Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.

Neratinib maleate (HKI-272 maleate) is an irreversible, orally active and highly selective inhibitor of HER2 and EGFR with IC50 values of 59 nM and 92 nM, respectively.Neratinib maleate has antitumor activity and can be used to treat gastrointestinal, respiratory, genitourinary, and cutaneous and musculoskeletal diseases, and can be used to study breast and prostate cancer. used in the study of breast and prostate cancer.

Neratinib-D6 is the deuterated form of Neratinib. Neratinib (T2325) (HKI-272) is an orally active, irreversible tyrosine kinase inhibitor that suppresses the activity of HER2 and EGFR, with IC50 values of 59 nM and 92 nM, respectively.